Craniocerebral Trauma Market

Market Overview:

The 7 major craniocerebral trauma markets are expected to exhibit a CAGR of 6.37% during 2024-2034.

The craniocerebral trauma market has been comprehensively analyzed in IMARC's new report titled "Craniocerebral Trauma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Craniocerebral trauma, also known as traumatic brain injury (TBI), refers to an injury that occurs when an external force traumatically affects the brain, causing neurological damage. The severity of this ailment can range from mild to severe and can lead to various cognitive, physical, and psychological impairments. Some common indications of the disease include persistent headaches, dizziness, sensitivity to light and noise, nausea, vomiting, confusion, fatigue, drowsiness, slurred speech, ringing in the ears, memory problems, temporary loss of consciousness, etc. Individuals suffering from this illness may also experience coma, changes in behavior or personality, paralysis, and even death. The diagnosis of craniocerebral trauma involves a comprehensive assessment that includes a medical history, a physical examination, and various neurological tests. The healthcare provider will also perform numerous imaging techniques, like computed tomography (CT) scans and magnetic resonance imaging (MRI), to visualize the brain and detect tissue damage, contusions, or any other abnormalities. In some cases, the Glasgow Coma Scale (GCS) is further utilized to evaluate a patient's level of consciousness and neurological function. 

The rising incidences of head injuries due to accidents, falls, physical assaults, etc., that can cause damage to the brain tissues are primarily driving the craniocerebral trauma market. In addition to this, the escalating cases of intracranial hemorrhage, which can result in increased pressure within the skull, leading to neurological deficits, are also creating a positive outlook for the market. Moreover, the widespread adoption of several effective medications, such as non-steroidal anti-inflammatory drugs, stimulants, antidepressants, etc., to alleviate the symptoms of the disease and enhance the quality of life for patients is further bolstering the market growth. Apart from this, the inflating application of decompressive craniectomy procedures, since they involve removing a portion of the skull to allow the swollen brain tissue to expand, thereby reducing pressure inside the cranial cavity, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of transcranial alternating current stimulation (tACS), which delivers alternating current to the brain to potentially synchronize neural activity and improve brain connectivity, is expected to drive the craniocerebral trauma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the craniocerebral trauma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for craniocerebral trauma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the craniocerebral trauma market in any manner.

Recent Developments:

• In April 2024, US Army officials, in partnership with Abbott, revealed that the company’s i-STAT TBI (Traumatic Brain Injury) cartridge had received clearance from the United States Food and Drug Administration to be used with whole blood.

Key Highlights:

• Every year, an estimated 5.48 million persons suffer from severe traumatic brain injury (TBI) (73 cases per 100,000).
• According to the WHO, low- and middle-income countries (LMICs), where 85% of the population lives, account for over 90% of all injury-related deaths.
• Every day, 153 persons in the United States die from injuries involving craniocerebral trauma.
• Among all age categories, motor vehicle accidents were the third overall greatest cause of craniocerebral trauma-related ED visits, hospitalizations, and deaths (14%).
• The rates were highest among people 75 and older.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the craniocerebral trauma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the craniocerebral trauma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current craniocerebral trauma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the craniocerebral trauma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the craniocerebral trauma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the craniocerebral trauma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of craniocerebral trauma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of craniocerebral trauma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of craniocerebral trauma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with craniocerebral trauma across the seven major markets?
• What is the size of the craniocerebral trauma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of craniocerebral trauma?
• What will be the growth rate of patients across the seven major markets?
   

Craniocerebral Trauma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for craniocerebral trauma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the craniocerebral trauma market?
• What are the key regulatory events related to the craniocerebral trauma market?
• What is the structure of clinical trial landscape by status related to the craniocerebral trauma market?
• What is the structure of clinical trial landscape by phase related to the craniocerebral trauma market?
• What is the structure of clinical trial landscape by route of administration related to the craniocerebral trauma market?